A phase II study of single-agent gefitinib as first-line therapy in patients with stage IV non-small-cell lung cancer

The aim of this study was to evaluate the efficacy and tolerability of gefitinib (‘IRESSA’) in Japanese patients with previously untreated stage IV non-small-cell lung cancer (NSCLC). This was a multi-institutional phase II study. Thirty-four patients with previously untreated stage IV NSCLC were en...

Descripción completa

Detalles Bibliográficos
Autores principales: Suzuki, R, Hasegawa, Y, Baba, K, Saka, H, Saito, H, Taniguchi, H, Yamamoto, M, Matsumoto, S, Kato, K, Oishi, T, Imaizumi, K, Shimokata, K
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361326/
https://www.ncbi.nlm.nih.gov/pubmed/16670714
http://dx.doi.org/10.1038/sj.bjc.6603159

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361326/
https://www.ncbi.nlm.nih.gov/pubmed/16670714
http://dx.doi.org/10.1038/sj.bjc.6603159

Ejemplares similares